Use of amisulpride as an anti-emetic
Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
1. A pharmaceutical composition comprising amisulpride in an amount of 2.5 mg per dose or 5 mg per dose, and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , comprising amisulpride in an amount of 2.5 mg per dose.
3. The pharmaceutical composition of claim 1 , comprising amisulpride in an amount of 5 mg per dose.
4. The pharmaceutical composition of claim 1 , wherein the amisulpride is (S)-amisulpride.
5. The pharmaceutical composition of claim 1 , wherein the amisulpride is in the form of a pharmaceutically acceptable salt.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for intravenous injection, intramuscular injection, or subcutaneous injection.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for intravenous injection.
8. The pharmaceutical composition of claim 7 , comprising a citrate buffer.
9. The pharmaceutical composition of claim 8 , comprising citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride.
10. The pharmaceutical composition of claim 9 , comprising 0.25% w/v amisulpride, citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride, wherein the pH of the pharmaceutical composition is 4-7.
11. The pharmaceutical composition of claim 10 , comprising 0.25% w/v amisulpride, 0.935% w/v citric acid monohydrate, 1.632% w/v trisodium citrate dihydrate, and 0.18% w/v sodium chloride.
12. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
13. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for sublingual or intranasal administration.
14. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for topical administration.
15. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for transdermal administration.
16. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for rectal administration.
17. A pharmaceutical composition formulated for intravenous injection comprising amisulpride in an amount of less than 50 mg per dose and a citrate buffer.
18. The pharmaceutical composition of claim 17 , comprising amisulpride in an amount of 1 mg to 35 mg per dose.
19. The pharmaceutical composition of claim 17 , comprising amisulpride in an amount of 1 mg to 20 mg per dose.
20. The pharmaceutical composition of claim 17 , comprising amisulpride in an amount of 2.5 mg to 20 mg per dose.
21. The pharmaceutical composition of claim 17 , comprising amisulpride in an amount of 2.5 mg per dose.
22. The pharmaceutical composition of claim 17 , comprising amisulpride in an amount of 5 mg per dose.
23. The pharmaceutical composition of claim 17 , comprising amisulpride in an amount of 20 mg per dose.
24. The pharmaceutical composition of claim 17 , wherein the amisulpride is (S)-amisulpride.
25. The pharmaceutical composition of claim 17 , wherein the amisulpride is in the form of a pharmaceutically acceptable salt.
26. The pharmaceutical composition of claim 17 , comprising citric acid monohydrate, trisodium citrate dihydrate, and sodium chloride.